D K Hossfeld
Overview
Explore the profile of D K Hossfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
1813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb H, et al.
Leukemia
. 2017 Aug;
31(11):2398-2406.
PMID: 28804124
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430)...
2.
Weh H, Kuse R, Seeger D, Suciu S, Hossfeld D
Leuk Lymphoma
. 2016 Jul;
3(5-6):423-7.
PMID: 27467434
Between 1981 and 1988, thirty-nine patients with acute myeloid leukemia (AML) following a de novo myelodysplastic syndrome (n-MDS) were studied cytogenetically. The chromosomal aberration rate was 59%. The anomalies most...
3.
Suciu S, Zeller W, Fiedler W, Weh H, Hossfeld D
Leuk Lymphoma
. 2016 Jul;
2(3-4):201-5.
PMID: 27456735
Eight patients with myelodysplastic syndrome (MDS) and chromosome abnormalities were studied by a combined method which allows simultaneous analysis of the karyotype and immunophenotype of the same mitotic cell. To...
4.
Miranda M, Lauseker M, Kraus M, Proetel U, Hanfstein B, Fabarius A, et al.
Leukemia
. 2016 Feb;
30(6):1255-62.
PMID: 26859076
Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs). Long-term survival with imatinib is excellent with a 8-year survival rate of...
5.
Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J, et al.
Leukemia
. 2015 Oct;
30(3):562-9.
PMID: 26464170
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited...
6.
Roy A, Cunningham D, Hawkins R, Sorbye H, Adenis A, Barcelo J, et al.
Br J Cancer
. 2012 Jul;
107(3):435-41.
PMID: 22767144
Background: Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum...
7.
Costa A, Van Hemelryck F, Aparicio A, Gatzemeier W, Leer J, Maillet B, et al.
Eur J Cancer
. 2010 Jul;
46(13):2340-3.
PMID: 20619635
One of the first reports on the state of medical education was published in 1910 in North America, with the support of the Carnegie Foundation, showing that the interest for...
8.
Schilling G, Bruweleit M, Harbeck N, Thomssen C, Becker K, Hoffmann R, et al.
Invest New Drugs
. 2008 Aug;
27(2):166-72.
PMID: 18696011
The purpose of this study was to evaluate the efficacy (progression free survival (PFS) and response rate) and safety of vinorelbine and trastuzumab combination chemotherapy in patients with HER2-overexpressing, metastatic...
9.
Frickhofen N, Berdel W, Opri F, Haas R, Schneeweiss A, Sandherr M, et al.
Bone Marrow Transplant
. 2006 Sep;
38(7):493-9.
PMID: 16980997
Ovarian cancer is chemosensitive, but most patients with advanced disease die from tumor progression. As 25% of the patients can be cured by chemotherapy, it is reasonable to evaluate high-dose...
10.
Becker K, Finke F, Geiges G, Gockel-Beining B, Hossfeld D, Miller K, et al.
Aktuelle Urol
. 2006 May;
37(3):201-4.
PMID: 16733822
Therapy with Docetaxel for hormone-refractory prostatic carcinoma has for the first time led to an increase in the survival time. Docetaxel has become established as a standard therapy for his...